According to BioIntel360, diabetes market in Mexico is expected to grow by 8.2% on annual basis to reach US$3,924.9 million in 2025. The diabetes market in the country has experienced robust growth d...
According to BioIntel360, diabetes market in Mexico is expected to grow by 8.2% on annual basis to reach US$3,924.9 million in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 8.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.0% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 3,625.8 million to approximately USD 5,554.8 million. Key Trends and Drivers in Mexico The Mexican market is experiencing an upward trend in CGM adoption, digital health integration, advanced therapeutic delivery systems, and evolving regulatory support. These trends will intensify over the next 2–4 years, fostering a shift toward data-driven care and refined reimbursement practices that could transform diabetes management in Mexico. Expand Continuous Glucose Monitoring Adoption • Mexican healthcare providers increasingly incorporate continuous glucose monitoring (CGM) devices into routine diabetes management. Pilot initiatives in major urban centers like Mexico City and Monterrey have begun integrating CGM data into patient monitoring protocols. • Recent provincial health publications and policy reviews from the last 12 months indicate that updated reimbursement guidelines support CGM adoption. Broader shifts in MedTech investment and clinical practice guidelines emphasize data-driven patient management. • The uptake of CGM devices is expected to intensify as reimbursement models are expanded and further clinical studies validate their utility. Increased use of real-time data is anticipated to improve treatment decision-making and patient monitoring practices. Integrate Digital Health for Remote Diabetes Management • Select healthcare networks in Mexico are adopting digital health solutions that facilitate remote patient monitoring and telemedicine. Several regional hospitals have initiated programs that combine digital dashboards with clinical data to improve diabetes care oversight. • Recent reviews from Mexican health agencies and industry reports highlight government-supported digital health initiatives to reduce care delivery costs and enhance access. The broader MedTech sector is witnessing funding and regulatory support shifts that encourage digital integration in chronic disease management. • Integration of digital health platforms is expected to expand, driven by policy refinements and demonstrated clinical benefits. Over the medium term, enhanced data connectivity may lead to better care coordination and consistent patient follow-up. Advanced Therapeutic Delivery Systems • Devices supporting accurate therapeutic delivery, such as smart insulin pens and connected insulin pumps, are emerging in Mexican clinical settings. Recent pilot programs in select clinics have evaluated these systems for monitoring dosing precision and treatment adherence. • Technological advancements and evidence from recent local studies support the development of these delivery systems. Updated reimbursement policies and medtech funding initiatives in Mexico have also contributed to the gradual adoption of advanced therapeutic devices. • The introduction and integration of these systems are expected to intensify as clinical guidelines evolve and additional data supporting their use become available. The market will likely see a steady increase in deployments as healthcare providers focus on precise therapeutic management. Regulatory and Reimbursement Frameworks • Mexican regulatory bodies are updating policies and reimbursement guidelines to better accommodate new diabetes devices and therapeutics. Recent policy releases and healthcare commission updates provide a framework for incorporating digital and connected devices into public health programs. • Broader healthcare cost-containment strategies and data from recent clinical evaluations are prompting regulatory adjustments. Publications from national and regional health authorities over the past 12 months emphasize the need for streamlined device approval and coverage protocols. • The evolving regulatory landscape is anticipated to intensify support for advanced diabetes devices and therapeutics, easing market entry for new solutions. A more defined reimbursement framework is expected to stimulate further investment and clinical uptake over the medium term. Competitive Landscape in Mexico The Mexican diabetes devices and therapeutics market currently features a mix of well-established companies and emerging local players. Strategic partnerships, mergers, and acquisitions are reshaping the competitive environment, supporting a trend toward digital integration and market consolidation. In the coming years, heightened competitive dynamics will drive further innovation and refine patient management solutions in Mexico. Current Market Conditions • The diabetes devices and therapeutics market in Mexico features a mix of established multinational companies and domestic players. Recent industry reports highlight a broadening product portfolio that spans traditional monitoring devices to connected therapeutic systems. Key Players and New Entrants • Multinational manufacturers hold substantial market share through longstanding relationships with Mexican healthcare institutions. These companies offer various devices that support monitoring and therapeutic needs. • New market entrants, including local startups, focus on digital health solutions tailored to Mexico’s healthcare environment. Recent studies indicate that these entrants are piloting niche solutions with regional hospitals and clinics. Examine Recent Partnerships, Mergers, and Acquisitions • Recent publications note that established players have partnered with digital health firms to integrate remote monitoring capabilities. • Mergers and acquisitions have been reported in the past 12 months, indicating a strategic consolidation to expand technological expertise and market reach. • Such collaborations and consolidations contribute to a more interconnected market landscape, with shared resources and joint innovation driving product development. Future Competitive Dynamics (2–4 Years) • The competitive landscape will shift as established players bolster their digital health portfolios and new entrants secure strategic partnerships. Increased consolidation and strategic alliances are projected to streamline product offerings and enhance regulatory compliance. • Over the next 2–4 years, the competitive environment will likely intensify, with clearer segmentation between companies focusing on traditional devices and those driving digital integration. This evolution will result in more targeted innovations and refined patient management strategies. This report provides a detailed data-centric analysis of the diabetes industry in Mexico, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. BioIntel360’s research methodology is based on industry best practices. Its unbiased analysis leverages a proprietary analytics platform to offer a detailed view of emerging business and investment market opportunities.
This report provides an in-depth, data-centric analysis of the Mexico diabetes devices and therapeutics market 2020-2029. Below is a summary of key market segments: Diabetes Devices and Therapeutics Market Share by Category • Diagnosis and Monitoring Devices • Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices • Blood Glucose Monitoring Devices • Insulin Delivery Devices • Diabetes Management and Mobile Applications • Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices • Self-Monitoring Blood Glucose Devices • Continuous Blood Glucose Monitoring Devices • Test Strips • Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices • Insulin Pumps • Insulin Pens • Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics • Oral Anti-Diabetic Drugs • Insulin • Non-Insulin Injectable Drugs • Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs • Alpha-Glucosidase Inhibitors • DPP-4 Inhibitors • SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin • Basal or Long-Acting • Bolus or Fast-Acting • Traditional Human Insulin Drugs • Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs • GLP-1 Receptor Agonists • Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs • Combination Insulin • Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration • Subcutaneous • Intravenous • Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes • Type 1 Diabetes • Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels • Online Pharmacies • Hospital Pharmacies • Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User • Hospitals • Diabetes Clinics • Homecare
• Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user. • Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly. • Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation.
1 Mexico Diabetes Devices and Therapeutics Market Size and Forecast, 2020-2029 2 Mexico Diabetes Devices and Therapeutics Market Share by Category, 2020-2029 2.1 Mexico Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, 2020-2029 2.2 Mexico Diabetes Devices and Therapeutics Market Size by Therapeutics, 2020-2029 3 Mexico Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices, 2020-2029 3.1 Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, 2020-2029 3.2 Diabetes Devices and Therapeutics Market Size by Insulin Delivery Devices, 2020-2029 3.3 Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, 2020-2029 3.4 Diabetes Devices and Therapeutics Market Size by Artificial Pancreas Devices, 2020-2029 4 Mexico Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices, 2020-2029 4.1 Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, 2020-2029 4.2 Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, 2020-2029 4.3 Diabetes Devices and Therapeutics Market Size by Test Strips, 2020-2029 4.4 Diabetes Devices and Therapeutics Market Size by Lancets, 2020-2029 5 Mexico Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices, 2020-2029 5.1 Diabetes Devices and Therapeutics Market Size by Insulin Pumps, 2020-2029 5.2 Diabetes Devices and Therapeutics Market Size by Insulin Pens, 2020-2029 5.3 Diabetes Devices and Therapeutics Market Size by Insulin Syringes, 2020-2029 6 Mexico Diabetes Devices and Therapeutics Market Share by Therapeutics, 2020-2029 6.1 Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, 2020-2029 6.2 Diabetes Devices and Therapeutics Market Size by Insulin, 2020-2029 6.3 Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, 2020-2029 6.4 Diabetes Devices and Therapeutics Market Size by Combination Drugs, 2020-2029 7 Mexico Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs, 2020-2029 7.1 Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors, 2020-2029 7.2 Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors, 2020-2029 7.3 Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors, 2020-2029 8 Mexico Diabetes Devices and Therapeutics Market Share by Insulin, 2020-2029 8.1 Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, 2020-2029 8.2 Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, 2020-2029 8.3 Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, 2020-2029 8.4 Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, 2020-2029 9 Mexico Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs, 2020-2029 9.1 Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, 2020-2029 9.2 Diabetes Devices and Therapeutics Market Size by Amylin Analogue, 2020-2029 10 Mexico Diabetes Devices and Therapeutics Market Share by Combination Drugs, 2020-2029 10.1 Diabetes Devices and Therapeutics Market Size by Combination Insulin, 2020-2029 10.2 Diabetes Devices and Therapeutics Market Size by Oral Combination, 2020-2029 11 Mexico Diabetes Devices and Therapeutics Market Share by Route of Administration, 2020-2029 11.1 Diabetes Devices and Therapeutics Market Size by Subcutaneous, 2020-2029 11.2 Diabetes Devices and Therapeutics Market Size by Intravenous, 2020-2029 11.3 Diabetes Devices and Therapeutics Market Size by Others, 2020-2029 12 Mexico Diabetes Devices and Therapeutics Market Share by Type of Diabetes, 2020-2029 12.1 Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, 2020-2029 12.2 Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, 2020-2029 13 Mexico Diabetes Devices and Therapeutics Market Share by Distribution Channels, 2020-2029 13.1 Diabetes Devices and Therapeutics Market Size by Online Pharmacies, 2020-2029 13.2 Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, 2020-2029 13.3 Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, 2020-2029 14 Mexico Diabetes Devices and Therapeutics Market Share by End User, 2020-2029 14.1 Diabetes Devices and Therapeutics Market Size by Hospitals, 2020-2029 14.2 Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, 2020-2029 14.3 Diabetes Devices and Therapeutics Market Size by Homecare, 2020-2029
Table 1: Mexico Diabetes Devices and Therapeutics Market Size by Value (US$ Million) 2020-2029 Table 2: Mexico Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, by Value (US$ Million), 2020-2029 Table 3: Mexico Diabetes Devices and Therapeutics Market Size by Therapeutics, by Value (US$ Million) 2020-2029 Table 4: Mexico Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Table 5: Mexico Diabetes Devices and Therapeutics Market Size by Insulin Delivery Devices, by Value (US$ Million) 2020-2029 Table 6: Mexico Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, by Value (US$ Million) 2020-2029 Table 7: Mexico Diabetes Devices and Therapeutics Market Size by Artificial Pancreas Devices, by Value (US$ Million) 2020-2029 Table 8: Mexico Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, by Value (US$ Million) 2020-2029 Table 9: Mexico Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Table 10: Mexico Diabetes Devices and Therapeutics Market Size by Test Strips, by Value (US$ Million) 2020-2029 Table 11: Mexico Diabetes Devices and Therapeutics Market Size by Lancets, by Value (US$ Million) 2020-2029 Table 12: Mexico Diabetes Devices and Therapeutics Market Size by Insulin Pumps, by Value (US$ Million) 2020-2029 Table 13: Mexico Diabetes Devices and Therapeutics Market Size by Insulin Pens, by Value (US$ Million) 2020-2029 Table 14: Mexico Diabetes Devices and Therapeutics Market Size by Insulin Syringes, by Value (US$ Million) 2020-2029 Table 15: Mexico Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, by Value (US$ Million), 2020-2029 Table 16: Mexico Diabetes Devices and Therapeutics Market Size by Insulin, by Value (US$ Million), 2020-2029 Table 17: Mexico Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, by Value (US$ Million), 2020-2029 Table 18: Mexico Diabetes Devices and Therapeutics Market Size by Combination Drugs, by Value (US$ Million), 2020-2029 Table 19: Mexico Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors (US$ Million), 2020-2029 Table 20: Mexico Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors (US$ Million), 2020-2029 Table 21: Mexico Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors (US$ Million), 2020-2029 Table 22: Mexico Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, by Value (US$ Million), 2020-2029 Table 23: Mexico Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, by Value (US$ Million), 2020-2029 Table 24: Mexico Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, by Value (US$ Million), 2020-2029 Table 25: Mexico Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, by Value (US$ Million), 2020-2029 Table 26: Mexico Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, by Value (US$ Million), 2020-2029 Table 27: Mexico Diabetes Devices and Therapeutics Market Size by Amylin Analogue, by Value (US$ Million), 2020-2029 Table 28: Mexico Diabetes Devices and Therapeutics Market Size by Combination Insulin, by Value (US$ Million), 2020-2029 Table 29: Mexico Diabetes Devices and Therapeutics Market Size by Oral Combination, by Value (US$ Million), 2020-2029 Table 30: Mexico Diabetes Devices and Therapeutics Market Size by Subcutaneous, by Value (US$ Million), 2020-2029 Table 31: Mexico Diabetes Devices and Therapeutics Market Size by Intravenous, by Value (US$ Million), 2020-2029 Table 32: Mexico Diabetes Devices and Therapeutics Market Size by Others, by Value (US$ Million), 2020-2029 Table 33: Mexico Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, by Value (US$ Million), 2020-2029 Table 34: Mexico Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, by Value (US$ Million), 2020-2029 Table 35: Mexico Diabetes Devices and Therapeutics Market Size by Online Pharmacies, by Value (US$ Million), 2020-2029 Table 36: Mexico Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, by Value (US$ Million), 2020-2029 Table 37: Mexico Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, by Value (US$ Million), 2020-2029 Table 38: Mexico Diabetes Devices and Therapeutics Market Size by Hospitals, by Value (US$ Million), 2020-2029 Table 39: Mexico Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, by Value (US$ Million), 2020-2029 Table 40: Mexico Diabetes Devices and Therapeutics Market Size by Homecare, by Value (US$ Million), 2020-2029
Figure 1: Mexico Diabetes Devices and Therapeutics Market Size by Value (US$ Million) 2020-2029 Figure 2: Mexico Diabetes Devices and Therapeutics Market Share by Category (%), 2020-2029 Figure 3: Mexico Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, by Value (US$ Million), 2020-2029 Figure 4: Mexico Diabetes Devices and Therapeutics Market Size by Therapeutics, by Value (US$ Million) 2020-2029 Figure 5: Mexico Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices (%), 2020-2029 Figure 6: Mexico Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Figure 7: Mexico Diabetes Devices and Therapeutics Market Size, by Insulin Delivery Devices, by Value (US$ Million) 2020-2029 Figure 8: Mexico Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, by Value (US$ Million) 2020-2029 Figure 9: Mexico Diabetes Devices and Therapeutics Market Size, by Artificial Pancreas Devices, by Value (US$ Million) 2020-2029 Figure 10: Mexico Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices (%), 2020-2029 Figure 11: Mexico Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, by Value (US$ Million) 2020-2029 Figure 12: Mexico Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Figure 13: Mexico Diabetes Devices and Therapeutics Market Size by Test Strips, by Value (US$ Million) 2020-2029 Figure 14: Mexico Diabetes Devices and Therapeutics Market Size by Lancets, by Value (US$ Million) 2020-2029 Figure 15: Mexico Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices (%), 2020-2029 Figure 16: Mexico Diabetes Devices and Therapeutics Market Share by Insulin Pumps, by Value (US$ Million) 2020-2029 Figure 17: Mexico Diabetes Devices and Therapeutics Market Share by Insulin Pens, by Value (US$ Million) 2020-2029 Figure 18: Mexico Diabetes Devices and Therapeutics Market Share by Insulin Syringes, by Value (US$ Million) 2020-2029 Figure 19: Mexico Diabetes Devices and Therapeutics Market Share by Therapeutics (%), 2020-2029 Figure 20: Mexico Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, by Value (US$ Million), 2020-2029 Figure 21: Mexico Diabetes Devices and Therapeutics Market Size by Insulin, by Value (US$ Million), 2020-2029 Figure 22: Mexico Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, by Value (US$ Million), 2020-2029 Figure 23: Mexico Diabetes Devices and Therapeutics Market Size by Combination Drugs, by Value (US$ Million), 2020-2029 Figure 24: Mexico Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs (%), 2020-2029 Figure 25: Mexico Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors (US$ Million), 2020-2029 Figure 26: Mexico Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors (US$ Million), 2020-2029 Figure 27: Mexico Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors (US$ Million), 2020-2029 Figure 28: Mexico Diabetes Devices and Therapeutics Market Share by Insulin (%), 2020-2029 Figure 29: Mexico Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, by Value (US$ Million), 2020-2029 Figure 30: Mexico Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, by Value (US$ Million), 2020-2029 Figure 31: Mexico Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, by Value (US$ Million), 2020-2029 Figure 32: Mexico Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, by Value (US$ Million), 2020-2029 Figure 33: Mexico Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs (%), 2020-2029 Figure 34: Mexico Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, by Value (US$ Million), 2020-2029 Figure 35: Mexico Diabetes Devices and Therapeutics Market Size by Amylin Analogue, by Value (US$ Million), 2020-2029 Figure 36: Mexico Diabetes Devices and Therapeutics Market Share by Combination Drugs (%), 2020-2029 Figure 37: Mexico Diabetes Devices and Therapeutics Market Size by Combination Insulin, by Value (US$ Million), 2020-2029 Figure 38: Mexico Diabetes Devices and Therapeutics Market Size by Oral Combination, by Value (US$ Million), 2020-2029 Figure 39: Mexico Diabetes Devices and Therapeutics Market Share by Route of Administration (%), 2020-2029 Figure 40: Mexico Diabetes Devices and Therapeutics Market Size by Subcutaneous, by Value (US$ Million), 2020-2029 Figure 41: Mexico Diabetes Devices and Therapeutics Market Size by Intravenous, by Value (US$ Million), 2020-2029 Figure 42: Mexico Diabetes Devices and Therapeutics Market Size by Others, by Value (US$ Million), 2020-2029 Figure 43: Mexico Diabetes Devices and Therapeutics Market Share by Type of Diabetes (%), 2020-2029 Figure 44: Mexico Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, by Value (US$ Million), 2020-2029 Figure 45: Mexico Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, by Value (US$ Million), 2020-2029 Figure 46: Mexico Diabetes Devices and Therapeutics Market Share by Distribution Channels (%), 2020-2029 Figure 47: Mexico Diabetes Devices and Therapeutics Market Size by Online Pharmacies, by Value (US$ Million), 2020-2029 Figure 48: Mexico Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, by Value (US$ Million), 2020-2029 Figure 49: Mexico Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, by Value (US$ Million), 2020-2029 Figure 50: Mexico Diabetes Devices and Therapeutics Market Share by End User (%), 2020-2029 Figure 51: Mexico Diabetes Devices and Therapeutics Market Size by Hospitals, by Value (US$ Million), 2020-2029 Figure 52: Mexico Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, by Value (US$ Million), 2020-2029 Figure 53: Mexico Diabetes Devices and Therapeutics Market Size by Homecare, by Value (US$ Million), 2020-2029
